An identical, complex TP53 mutation arising independently in two unrelated families with diverse cancer profiles: the complexity of interpreting cancer risk in carriers
Most inherited TP53 mutations have been identified in individuals with a family cancer predisposition syndrome, in which the activity of p53 mutants is severely reduced. However, germline p53 mutants in children with ‘sporadic’ adrenocortical or choroid plexus tumors exhibit a wide range of function...
Gespeichert in:
Veröffentlicht in: | Oncogenesis (New York, NY) NY), 2012-02, Vol.1 (2), p.e1-e1 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Most inherited
TP53
mutations have been identified in individuals with a family cancer predisposition syndrome, in which the activity of p53 mutants is severely reduced. However, germline p53 mutants in children with ‘sporadic’ adrenocortical or choroid plexus tumors exhibit a wide range of functional activity. Here, we demonstrate the occurrence of a complex germline
TP53
mutation in two unrelated families with different cancer phenotypes, neither fulfilling the classic criteria for Li-Fraumeni syndrome. The
TP53
mutation consists of a duplication of 7 bp in exon 4, resulting in a frame shift and premature stop signal. Haplotype analysis indicated that the mutation arose independently in the two families. Analysis of the DNA secondary structure predicts the
TP53
mutation occurred within a hairpin loop. Additional germline complex mutations occurring within the same region of exon 4 have been identified in the IARC database. Our findings suggest that certain
TP53
regions are prone to intrinsic genetic alterations, possibly through defects in DNA replication or repair. Further, carriers of the same
TP53
mutation can have diverse cancer profiles, illustrating the complexity of genetic counseling and risk prediction. |
---|---|
ISSN: | 2157-9024 2157-9024 |
DOI: | 10.1038/oncsis.2012.1 |